TY - JOUR
T1 - Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome
T2 - A population-based analysis
AU - Mackay, Tara M.
AU - van Erning, Felice N.
AU - van der Geest, Lydia G.M.
AU - de Groot, Jan Willem B.
AU - Haj Mohammad, Nadia
AU - Lemmens, Valery E.
AU - van Laarhoven, Hanneke W.
AU - Besselink, Marc G.
AU - Wilmink, Johanna W.
N1 - Funding Information:
The Dutch Pancreatic Cancer Project, including the Netherlands Cancer Registry, received funding from the Dutch Cancer Society ( KWF Kankerbestrijding ; grant no. UVA2013-5842 ). The funding source played no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.
Funding Information:
The Dutch Pancreatic Cancer Project, including the Netherlands Cancer Registry, received funding from the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842). The funding source played no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.
Publisher Copyright:
© 2018 Elsevier Ltd
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: The relation between the primary origin of metastasised pancreatic ductal adenocarcinoma (PDAC)—head, body or tail—metastatic patterns and outcomes has not yet been investigated in large population-based studies. Methods: Patients with metastasised PDAC at diagnosis from the Netherlands Cancer Registry were included (2005–2015). We compared number of metastatic organ sites (1, 2, ≥3) and specific metastatic organ sites (peritoneum, liver, lung and extra-regional lymph nodes) for the different primary tumour locations. Cox regression analyses were used to determine the association of tumour location and metastatic organ site(s) with overall survival. Results: Overall, we included 9952 patients with metastasised PDAC. The primary origin was head in 5644 (57%), body in 1671 (17%) and tail in 2637 (26%) patients. Differences between primary origins were the number of metastatic organ sites (proportions ≥3 sites for head: 4%, for body: 8% and for tail: 13%, p < 0.0001) and peritoneal metastases (present in 13% for head, 24% for body and 30% for tail; p < 0.0001). Median overall survival was 2.6 months for head PDAC (reference), 2.4 months for body PDAC (HR 1.02 [0.97–1.08]) and 1.9 months for tail PDAC (HR 1.20 [1.15–1.26]). Of patients with one metastatic organ site, the worst survival compared with other sites was seen with liver only metastases (2.5 months vs. 2.7–5.1 months), and the best survival for patients, with extra-regional lymph node only metastases (5.1 months). Conclusion: Metastatic patterns differ among the primary origins for PDAC with metastasised tail tumours having more metastatic sites, more often peritoneal metastases and worse survival.
AB - Introduction: The relation between the primary origin of metastasised pancreatic ductal adenocarcinoma (PDAC)—head, body or tail—metastatic patterns and outcomes has not yet been investigated in large population-based studies. Methods: Patients with metastasised PDAC at diagnosis from the Netherlands Cancer Registry were included (2005–2015). We compared number of metastatic organ sites (1, 2, ≥3) and specific metastatic organ sites (peritoneum, liver, lung and extra-regional lymph nodes) for the different primary tumour locations. Cox regression analyses were used to determine the association of tumour location and metastatic organ site(s) with overall survival. Results: Overall, we included 9952 patients with metastasised PDAC. The primary origin was head in 5644 (57%), body in 1671 (17%) and tail in 2637 (26%) patients. Differences between primary origins were the number of metastatic organ sites (proportions ≥3 sites for head: 4%, for body: 8% and for tail: 13%, p < 0.0001) and peritoneal metastases (present in 13% for head, 24% for body and 30% for tail; p < 0.0001). Median overall survival was 2.6 months for head PDAC (reference), 2.4 months for body PDAC (HR 1.02 [0.97–1.08]) and 1.9 months for tail PDAC (HR 1.20 [1.15–1.26]). Of patients with one metastatic organ site, the worst survival compared with other sites was seen with liver only metastases (2.5 months vs. 2.7–5.1 months), and the best survival for patients, with extra-regional lymph node only metastases (5.1 months). Conclusion: Metastatic patterns differ among the primary origins for PDAC with metastasised tail tumours having more metastatic sites, more often peritoneal metastases and worse survival.
KW - Body
KW - Chemotherapy
KW - Head
KW - Metastases
KW - Pancreatic ductal adenocarcinoma
KW - Survival
KW - Tail
UR - http://www.scopus.com/inward/record.url?scp=85056930292&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2018.10.008
DO - 10.1016/j.ejca.2018.10.008
M3 - Article
C2 - 30476732
SN - 0959-8049
VL - 106
SP - 99
EP - 105
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -